No headlines found.
Globe Newswire (Mon, 10-Mar 4:05 PM ET)
Globe Newswire (Thu, 6-Mar 9:00 PM ET)
PRNewswire (Mon, 24-Feb 5:05 PM ET)
Globe Newswire (Mon, 24-Feb 4:13 PM ET)
Globe Newswire (Mon, 24-Feb 12:07 PM ET)
PRNewswire (Mon, 24-Feb 5:45 AM ET)
Globe Newswire (Sat, 22-Feb 9:19 AM ET)
Globe Newswire (Fri, 21-Feb 1:45 PM ET)
February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU
PRNewswire (Fri, 21-Feb 5:45 AM ET)
Globe Newswire (Thu, 20-Feb 1:28 PM ET)
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Caribou Biosciences trades on the NASDAQ stock market under the symbol CRBU.
As of April 1, 2025, CRBU stock price declined to $0.84 with 774,968 million shares trading.
CRBU has a beta of 2.43, meaning it tends to be more sensitive to market movements. CRBU has a correlation of 0.16 to the broad based SPY ETF.
CRBU has a market cap of $78.23 million. This is considered a Micro Cap stock.
Last quarter Caribou Biosciences reported $2 million in Revenue and -$.39 earnings per share. This beat revenue expectation by $237,000 and exceeded earnings estimates by $.03.
In the last 3 years, CRBU traded as high as $13.19 and as low as $.84.
The top ETF exchange traded funds that CRBU belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
CRBU has underperformed the market in the last year with a price return of -83.6% while the SPY ETF gained +8.6%. CRBU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.1% and -17.5%, respectively, while the SPY returned -4.0% and -0.8%, respectively.
CRBU support price is $.86 and resistance is $.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBU shares will trade within this expected range on the day.